Initiate Consultancy has secured equity investment from Queen’s Park Equity to facilitate a management buyout and expand its global market access and consultancy services.

Target Company Overview

Initiate Consultancy, a specialist consultancy based in the UK, operates within the pharmaceutical, medical device, and diagnostics sectors globally. Recently, Initiate secured new equity investment aimed at facilitating a management buyout while also propelling its expansion strategies. The investment comes from Queen’s Park Equity (QPE) and will enable the leadership team to enhance their global market access capabilities, expand service delivery, and pursue strategic acquisitions. With offices in Northampton, London, and Zug, Switzerland, Initiate is a recognized leader in Market Access and Health Economics and Outcomes Research (HEOR), offering a broad range of services including HTA strategy and submissions, cost-effectiveness modeling, evidence synthesis, payer research, and value communication.

Initiate delivers data-driven access solutions across more than 50 countries, with a particular emphasis on oncology and rare diseases. This expertise positions the company favorably within its field, especially as the demand for innovative therapies and market access strategies continues to grow.

Industry Overview in the UK

The UK market for pharmaceuticals and healthcare consulting is robust, marked by steady growth driven by advancements in medical technologies and shifting regulatory landscapes. Notably, the National Health Service (NHS) and various regulatory bodies shape the market dynamics, es